Showing 20 of 56 recruiting trials for “primary-pulmonary-lymphoma”
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
👨⚕️ Jean-Francois Larouche, CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Quebec City, QC Canada📍 8 sites📅 Started Feb 2024View details ↗
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients
👨⚕️ Bastian von Tresckow, Prof. Dr. med., University Hospital, Essen📍 2 sites📅 Started Nov 2023View details ↗
Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)
RecruitingNCT05828628 ↗
CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL
Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma
The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Oct 2022View details ↗
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
👨⚕️ Qingming Wang, M.D., Second Affiliated Hospital of Nanchang University📍 1 site📅 Started Aug 2022View details ↗
Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
🏥 Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Aug 2022View details ↗
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
👨⚕️ James Rubenstein, MD, PhD, University of California, San Francisco📍 1 site📅 Started Jun 2022View details ↗
Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)
🏥 Affiliated Hospital to Academy of Military Medical Sciences📍 1 site📅 Started Jun 2022View details ↗
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
🏥 Federal Research Institute of Pediatric Hematology, Oncology and Immunology📍 1 site📅 Started May 2022View details ↗
Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL
Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma
High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →